Fatima Kakkar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fatima Kakkar has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Bruce Tapiero
Infectious Disease Division, Department of Paediatrics, CHU Sainte Justine, Université de Montréal, 3175 Ch. de la Cote-Sainte-Catherine (bureau 7412), Montréal, H3T1C5 QC, Canada
1 shared publication - Céline Rousseau
Infectious Disease Division, Department of Paediatrics, CHU Sainte Justine, Université de Montréal, 3175 Ch. de la Cote-Sainte-Catherine (bureau 7412), Montréal, H3T1C5 QC, Canada
1 shared publication - Hermione Lyall
Children's Services, Imperial College Healthcare NHS Trust, London, UK
1 shared publication - Jean-Baptiste Le Meur
Department of Social and Preventive Medicine, Faculty of Medicine, Laval University, Pavillon Ferdinand-Vandry (bureau 4633), 1050 Av de la Medicine, Québec, G1V0A6, QC, Canada
1 shared publication - Jeanne Sibiude
E Groupe Hospitalier Cochin Port Royal , Université Paris Descartes , Paris , France
1 shared publication - Lena Coic
Infectious Disease Division, Department of Paediatrics, CHU Sainte Justine, Université de Montréal, 3175 Ch. de la Cote-Sainte-Catherine (bureau 7412), Montréal, H3T1C5 QC, Canada
1 shared publication
Latest Publications
- 6 September 2016
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 15 (11) , 1501-1513
Surveillance monitoring for safety of in utero antiretroviral therapy exposures: current strategies and challenges
Introduction: The use of antiretroviral therapy (ART) in pregnancy to prevent vertical HIV transmission has been one of the most successful public health programs in the last decade. As a result, an unprecedented number of women are taking ART at conception and during pregnancy. Given few randomized studies evaluating safety of different ART regimens in pregnancy, ongoing drug safety surveillance is critical. Areas covered: This review aims to provide a rationale for ART drug safety surveillance, describe changing patterns of ART use and summarize current surveillance efforts in both low-resource and high-resource settings. Additionally, biostatistical approaches to and challenges in analysis of observational surveillance data are discussed. Expert opinion: The global landscape of ART use in pregnancy is rapidly increasing and evolving. Any increase in adverse effects of in-utero exposure to ART has the potential to reduce the impact of improvements in infant morbidity and mortality gained from decreased vertical HIV transmission. ART drug safety surveillance should therefore be a critical piece of programs to prevent mother to child transmission in both high- and low-resource settings. Current surveillance efforts could be strengthened with long-term follow-up of exposed children, pooling of data across cohorts and standardized approaches to analysis.
- 6 September 2016
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 15 (11) , 1501-1513
Surveillance monitoring for safety of in utero antiretroviral therapy exposures: current strategies and challenges
Introduction: The use of antiretroviral therapy (ART) in pregnancy to prevent vertical HIV transmission has been one of the most successful public health programs in the last decade. As a result, an unprecedented number of women are taking ART at conception and during pregnancy. Given few randomized studies evaluating safety of different ART regimens in pregnancy, ongoing drug safety surveillance is critical. Areas covered: This review aims to provide a rationale for ART drug safety surveillance, describe changing patterns of ART use and summarize current surveillance efforts in both low-resource and high-resource settings. Additionally, biostatistical approaches to and challenges in analysis of observational surveillance data are discussed. Expert opinion: The global landscape of ART use in pregnancy is rapidly increasing and evolving. Any increase in adverse effects of in-utero exposure to ART has the potential to reduce the impact of improvements in infant morbidity and mortality gained from decreased vertical HIV transmission. ART drug safety surveillance should therefore be a critical piece of programs to prevent mother to child transmission in both high- and low-resource settings. Current surveillance efforts could be strengthened with long-term follow-up of exposed children, pooling of data across cohorts and standardized approaches to analysis.
- Open Access
- 15 March 2016
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 16 (1) , 1-8
Awareness of cytomegalovirus and risk factors for susceptibility among pregnant women, in Montreal, Canada
Advances in diagnostic and therapeutic modalities for congenital cytomegalovirus (CMV) infection have generated a mounting interest in identifying mothers susceptible to CMV. The objectives of this study were to evaluate the prevalence and socio-demographic determinants of CMV susceptibility and CMV awareness, among pregnant women, in Montreal, Quebec. Between April and December 2012, women delivering at Centre Hospitalier Universitaire Sainte Justine were recruited for the study. Stored serum from the first trimester of pregnancy was tested for CMV IgG. Knowledge about CMV and socio-demographic characteristics were collected via standardized questionnaire. Four hundred and ninety one women were enrolled in the study. Overall, 225 mothers (46 %) were seronegative for CMV, and 85 % (n = 415) were unaware of CMV or the associated risks in pregnancy. Significant risk factors for CMV seronegative status included Canadian vs. foreign born (aOR 6.88, 95 % CI 4.33–10.94), and high vs. low family income (aOR 4.68, 95 % CI 2.09–10.48). Maternal employment status was the only significant predictor of CMV unawareness, with unemployed mothers at the highest risk (aOR 85.6, 95 % CI 17.3–421.3). Nearly half of pregnant women studied were at risk of primary infection, and yet, the majority was unaware of potential risks associated with CMV. Canadian born mothers and those with a high socioeconomic status were more likely to be CMV seronegative. Increased education about CMV infection, through public health interventions and obstetrician/pediatric counseling, is needed for all pregnant women.
- 15 March 2016
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 16 (1) , 1-8
Open AccessAwareness of cytomegalovirus and risk factors for susceptibility among pregnant women, in Montreal, Canada
Advances in diagnostic and therapeutic modalities for congenital cytomegalovirus (CMV) infection have generated a mounting interest in identifying mothers susceptible to CMV. The objectives of this study were to evaluate the prevalence and socio-demographic determinants of CMV susceptibility and CMV awareness, among pregnant women, in Montreal, Quebec. Between April and December 2012, women delivering at Centre Hospitalier Universitaire Sainte Justine were recruited for the study. Stored serum from the first trimester of pregnancy was tested for CMV IgG. Knowledge about CMV and socio-demographic characteristics were collected via standardized questionnaire. Four hundred and ninety one women were enrolled in the study. Overall, 225 mothers (46 %) were seronegative for CMV, and 85 % (n = 415) were unaware of CMV or the associated risks in pregnancy. Significant risk factors for CMV seronegative status included Canadian vs. foreign born (aOR 6.88, 95 % CI 4.33–10.94), and high vs. low family income (aOR 4.68, 95 % CI 2.09–10.48). Maternal employment status was the only significant predictor of CMV unawareness, with unemployed mothers at the highest risk (aOR 85.6, 95 % CI 17.3–421.3). Nearly half of pregnant women studied were at risk of primary infection, and yet, the majority was unaware of potential risks associated with CMV. Canadian born mothers and those with a high socioeconomic status were more likely to be CMV seronegative. Increased education about CMV infection, through public health interventions and obstetrician/pediatric counseling, is needed for all pregnant women.